paediatrics Brussels 17

Ramaswamy et al

Table A1. Multivariable Cox Proportional Hazards Model of Survival Across All Posterior Fossa Ependymomas

PFS

OS

P

P

Variable

HR (95% CI)

HR (95% CI)

GENE cohort (PFS, n = 304; OS, n = 305) Subgroup EPN_PFA

2.66 (1.14 to 6.23) 0.97 (0.95 to 0.99) 1.87 (1.31 to 2.67) 0.30 (0.21 to 0.44) 1.07 (0.74 to 1.55) 1.19 (0.86 to 1.66) 2.08 (0.65 to 6.66) 1.00 (0.97 to 1.03) 1.59 (0.91 to 2.79) 0.70 (0.43 to 1.14) 0.95 (0.51 to 1.79) 1.17 (0.73 to 1.90) 1.40 (0.25 to 7.96) 0.99 (0.89 to 1.10) 2.75 (1.42 to 5.33) 2.16 (1.15 to 4.06) 2.49 (0.98 to 6.35) 0.99 (0.96 to 1.02) 2.03 (1.43 to 2.89) 1.11 (0.74 to 1.66) 0.99 (0.65 to 1.49) 1.10 (0.76 to 1.58)

.02

6.11 (1.38 to 27.01) 0.96 (0.93 to 0.99) 2.37 (1.55 to 3.64) 0.29 (0.18 to 0.45) 0.75 (0.47 to 1.20) 1.26 (0.83 to 1.89) 6.95 (1.13 to 42.71) 1.01 (0.97 to 1.05) 1.79 (0.87 to 3.70) 0.62 (0.33 to 1.17) 0.79 (0.37 to 1.72) 2.12 (1.07 to 4.21) 4.94 (0.43 to 698.63) 1.05 (0.91 to 1.17) 3.27 (1.47 to 6.90) 2.72 (1.23 to 6.74) 2.72 (0.51 to 14.67) 0.98 (0.93 to 1.04) 2.00 (1.19 to 3.37) 1.08 (0.60 to 1.95) 1.38 (0.71 to 2.66) 0.85 (0.50 to 1.45)

.02 .02

Age

.008

Incomplete resection

, .001 , .001

, .001 , .001

Adjuvant fi rst-line radiation

Adjuvant fi rst-line chemotherapy

.72 .30

.23 .28

Male

CERN cohort (PFS, n = 120; OS, n = 120) Subgroup EPN_PFA

.22 .89 .10 .15 .88 .51

.04 .73 .12 .14 .56 .03

Age

Incomplete resection

Adjuvant fi rst-line radiation

Adjuvant fi rst-line chemotherapy

Male

St Jude RT1 cohort (PFS, n = 112; OS, n = 112) Subgroup EPN_PFA

.70 .87

.23 .51

Age

Incomplete resection

.003 .009

.005

Male

.01

Burdenko cohort (PFS, n = 241; OS, n = 241) Subgroup EPN_PFA

.06 .61

.24 .49

Age

Incomplete resection

, .001

.009

Adjuvant fi rst-line radiation

.61 .94 .62

.80 .34 .55

Adjuvant fi rst-line chemotherapy

Male

Abbreviations: CERN, Collaborative Ependymoma Research Network; GENE, Global Ependymoma Network of Excellence; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.

Table A2. Multivariable Cox Proportional Hazards Regression Model of 10-Year Progression-Free and Overall Survival Variable Hazard Ratio 95% CI P Progression-free survival (n = 777) Age 0.99 0.97 to 1.00 .09 Male 1.25 1.01 to 1.54 .04 Incomplete resection 1.88 1.51 to 2.33 , .001 Adjuvant fi rst-line radiation 0.63 0.50 to 0.81 , .001 Adjuvant fi rst-line chemotherapy 1.02 0.79 to 1.32 .87 EPN_PFA subgroup 2.18 1.31 to 3.62 .003 Overall survival (n = 778) Age 0.98 0.96 to 1.00 .13 Male 1.40 1.06 to 1.84 .02 Incomplete resection 2.14 1.61 to 2.84 , .001 Adjuvant fi rst-line radiation 0.52 0.38 to 0.71 , .001 Adjuvant fi rst-line chemotherapy 0.91 0.66 to 1.27 .6 EPN_PFA Subgroup 4.27 1.86 to 9.81 , .001

J OURNAL OF C LINICAL O NCOLOGY

© 2016 by American Society of Clinical Oncology

from 139.18.224.1 Information downloaded from jco.ascopubs.org and provided by at UNIVERSITAETSKLINIKUM LEIPZIG on June 20, 2016 Copyright © 2016 American S ciety of Clinical Oncology. All rights reserved.